Advertisement

Topics

Search Results for "En Vivo EVP6124 Alzheimer"

09:35 EDT 1st July 2016 | BioPortfolio

Matching Channels

Cytoplasmic Protein Tau

One of the main pillars of current drug discovery and development activities in the pharmaceutical industry for Alzheimer's disease is prevention of the accumulation of misfolded proteins, i.e. ...

Histone Deacetylase HDAC Inhibitors

Histone deacetylase (HDAC) inhibitors are emerging as a new class of potential anticancer agents for the treatment of solid and hematological malignancies. HDAC inhibition causes acetylated nuclear ...

Nerve growth factor NGF

Nerve growth factor (NGF) is the prototypical member of the family of neurotrophin growth factors that are involved in the growth and survival of nervous tissue. NGF and its receptors, the tyrosine-...

Interleukin 1 IL 1 Receptor IL 1R

Interleukin-1 (IL-1) beta is a proinflammatory cytokine driving joint inflammation as well as systemic signs of inflammation, such as fever and acute phase protein production. Current therapy targetin...

Selective monoamine oxidase type B MAOB inhibitors

The clinical benefit of monoamine oxidase type B (MAO-B) inhibitors is thought to arise from an ability of these medications to enhance the level of dopamine by decreasing the catabolism. Additional...

Matching News

Functional screening of Alzheimer risk loci identifies PTK2B as an in vivo modulator and early marker of Tau pathology

Alzheimer's Association awards $4.3 million to accelerate the launch of new drug treatment

(Alzheimer's Association) The Alzheimer's Association announces a new $4.3 million research grant for a new phase of the Dominantly Inherited Alzheimer's Network Trials Unit known as DIAN-TU Next Gene...

ALZHEIMER: Le Bexarotène ou l'espoir d'un traitement efficace? - Science Advances

La question est posée avec le bexarotène « suspecté » de pouvoir prévenir la maladie d'Alzheimer avant même l'apparition des symptômes. Ce...

Vivo Capital closes new early stage fund

Vivo Capital closed its new Vivo Panda fund with more than $100 million to invest primarily in early stage healthcare companies, including biotech, medtech and diagnostics. Vivo said the new fund will...

Vivo Capital raises $100M-plus for health care fund

Over $100 million has been secured for the Vivo Panda fund, a new fund by Vivo Capital dedicated to early-stage medtech, diag -More- 

Vivo Capital Closes $100 Million Fund for Early-Stage US-China Healthcare Companies

Vivo Capital, a California-China healthcare investment firm, has closed an early stage healthcare VC fund, the Vivo PANDA Fund with more than $100 million. Traditionally, Vivo has looked for late...

Alzheimer’s Disease and Diabetes Mellitus

Alzheimer’s Disease and Diabetes Mellitus Larry H. Bernstein, MD, FCAP, Curator LPBI   Unraveling Alzheimer’s:Making Sense of the Relationship between Diabetes and Alzheimer’s Disease1 ...

Alzheimer funding analyzer launched on Journal of Alzheimer's Disease website

(IOS Press) The Journal of Alzheimer's Disease (JAD) is proud to announce the launch of the Alzheimer's Funding Analyzer (AFA) on the JAD website. It is a free service that is part of a new suite of o...

Matching PubMed Articles

Prolonged In Vivo Retention of a Cathepsin D Targeted Optical Contrast Agent in a Mouse Model of Alzheimer's Disease.

Cathepsin D (CatD) is a lysosomal protease that is elevated early in Alzheimer's disease (AD). We have previously developed a Targeted contrast agent (CA) to detect CatD activity in vivo, consisting o...

Quantitative MRI to understand Alzheimer's disease pathophysiology.

The role of white matter damage in the progression of Alzheimer's disease and the associated cognitive symptoms is becoming increasingly clearer. This is partly because of the advent of diffusion tens...

In vivo cortical spreading pattern of tau and amyloid in the Alzheimer's disease spectrum.

To determine the in vivo cortical spreading pattern of tau and amyloid and to establish positron emission tomography (PET) image-based tau staging in Alzheimer's disease (AD) spectrum.

Insights into White Matter Damage in Alzheimer's Disease: From Postmortem to in vivo Diffusion Tensor MRI Studies.

Alzheimer's disease (AD) has traditionally been considered a disease of the gray matter (GM). However, several pathological and neuroimaging studies provided evidence of white matter (WM) abnormalitie...

Kallikrein-8 inhibition attenuates Alzheimer's pathology in mice.

Memory loss and increased anxiety are clinical hallmarks of Alzheimer's disease (AD). Kallikrein-8 is a protease implicated in memory acquisition and anxiety, and its mRNA is known to be up-regulated ...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement